Technical Analysis for ACST - Acasti Pharma, Inc.

Grade Last Price % Change Price Change
grade D 1.27 -2.31% -0.03
ACST closed down 2.31 percent on Tuesday, June 27, 2017, on 75 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ACST trend table...

Date Alert Name Type % Chg
Jun 27 Fell Below 50 DMA Bearish 0.00%
Jun 27 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jun 27 180 Bearish Setup Bearish Swing Setup 0.00%
Jun 26 Crossed Above 50 DMA Bullish -2.31%
Jun 26 Stochastic Buy Signal Bullish -2.31%

Older signals for ACST ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Get Started for Free!
Basic chart:

Profile
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for abnormalities in blood lipids, and the treatment and prevention of cardiovascular disorders. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
Is ACST a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jun 16 CORRECTION: Acasti Pharma Grants Stock Options
Jun 14 Acasti Pharma Grants Stock Options
Jun 12 Acasti Pharma To Present at Upcoming International Industry Conferences
Jun 6 Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results
May 31 Acasti Pharma and CordenPharma Announce Large Scale Production of CaPre® with New Continuous Manufacturing Process
May 18 Acasti Pharma Presents CaPre Clinical Data at National Lipid Association Scientific Sessions
Apr 24 Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities
Apr 12 Acasti Pharma to Present CaPre Omega-3 Bridging Study Results at National Lipid Association Scientific Sessions
Mar 30 Acasti Pharma Provides Update On CaPre Phase 3 Development Program
Mar 8 Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading Cardiovascular Disease Experts
See more ACST news...
Indicators
Indicator Value
52 Week High 3.09
52 Week Low 1.11
Average Volume 30,026
200-Day Moving Average 1.3694
50-Day Moving Average 1.2856
20-Day Moving Average 1.2928
10-Day Moving Average 1.301
Average True Range 0.0601
ADX 33.28
+DI 27.91
-DI: 15.12
Chandelier Exit (Long, 3 ATRs) 1.3297
Chandelier Exit (Short, 3 ATRs) 1.4103
Upper Bollinger Band 1.3905
Lower Bollinger Band 1.1951
Percent B (%b) 0.38
Bandwidth 0.151145
MACD Line -0.0015
MACD Signal Line 0.003
MACD Histogram -0.0045